The Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) on November 25 and set a price target ...

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Gilead Sciences demonstrated positive momentum on the NASDAQ, with shares climbing 0.6 percent to $91.88. This upward trajectory is primarily attributed to groundbreaking results from clinical trials ...

In addition, we kept open the possibility that the ETF will continue to rise and could reach around 108.45. To see how we ...

In a report released on November 25, Brian Abrahams from RBC Capital maintained a Hold rating on Neurocrine (NBIX – Research Report), with a ...

Outlook Therapeutics OTLK reported preliminary top-line results from the 90-day non-inferiority NORSE EIGHT clinical study ...

Applied Therapeutics APLT announced that the FDA has issued a Complete Response Letter (CRL) for the new drug application ...

A cancer treatment similar to sac-TMT approved for marketing in China is Trodelvy (sacituzumab govitecan-hziy), developed by ...

Gilead (GILD) announced The New England Journal of Medicine, or NEJM, published the full results from the company’s pivotal ...

For oral medications that prevent new HIV infection to be effective, the patient must take certain actions, including ...